Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): Comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes

被引:230
作者
Cannon, Christopher P. [1 ]
Giugliano, Robert P. [1 ]
Blazing, Michael A. [2 ]
Harrington, Robert A. [2 ]
Peterson, John L. [2 ,4 ]
Sisk, Christine McCrary
Strony, John [3 ]
Musliner, Thomas A.
McCabe, Carolyn H. [1 ,3 ]
Veltri, Enrico
Braunwald, Eugene [1 ]
Califf, Robert M. [2 ]
机构
[1] Brigham & Womens Hosp, Div Cardiovasc, TIMI Study Grp, Boston, MA 02115 USA
[2] Duke Clin Res Inst, Durham, NC USA
[3] Merck & Co Inc, Rahway, NJ 07065 USA
[4] Schering Plough Corp, Kenilworth, NJ USA
关键词
D O I
10.1016/j.ahj.2008.07.023
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Reduction in low-density lipoprotein cholesterol (LDL-C) improves clinical outcomes in patients with chronic coronary artery disease and acute coronary syndromes (ACSs). The combination of ezetimibe/simvastatin produces greater reductions in LDL-C compared to simvastatin monotherapy. The IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) is a multicenter, randomized, double-blind, active-control trial designed to test the hypothesis that the addition of ezetimibe to statin therapy, using ezetimibe/simvastatin, will translate into increased clinical benefit on cardiovascular outcomes relative to simvastatin monotherapy in patients with ACS. Study Design The study will recruit up to 18,000 moderate- to high-risk patients stabilized after ACS. Patients are randomized in a 1:1 ratio to once-daily doses of either ezetimibe/simvastatin 10/40 mg or simvastatin monotherapy 40 mg. Follow-up visits are at I and 4 months, and every 4 months thereafter. If consecutive measures of LDL-C are >79 mg/dL at follow-up visits, the simvastatin dose will be increased to 80 mg in a double-blind manner. The primary end point is the first occurrence of cardiovascular death, nonfatal myocardial infarction, rehospitalization for unstable angina, coronary revascularization (occurring at least 30 days after randomization), or stroke. Patients will be followed for a minimum of 2.5 years and until at least 5,250 patients experience a primary end point. Summary IMPROVE-IT will determine whether the addition of ezetimibe to statin therapy, using ezetimibe/simvastatin, improves cardiovascular outcomes compared with simvastatin monotherapy in patients after ACS. In addition, the difference in achieved LDL-C levels between the groups will provide data on whether the target for LDL-C lowering should be reduced further. (Am Heart J 2008; 156:826-32.)
引用
收藏
页码:826 / 832
页数:7
相关论文
共 32 条
[1]   Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [J].
Baigent, C ;
Keech, A ;
Kearney, PM ;
Blackwell, L ;
Buck, G ;
Pollicino, C ;
Kirby, A ;
Sourjina, T ;
Peto, R ;
Collins, R ;
Simes, J .
LANCET, 2005, 366 (9493) :1267-1278
[2]  
Ballantyne CM, 1998, AM J CARDIOL, V82, p3Q
[3]   Prevention and Rehabilitation - Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: The Vytorin Versus Atorvastatin (VYVA) Study [J].
Ballantyne, CM ;
Abate, N ;
Yuan, Z ;
King, TR ;
Palmisano, J .
AMERICAN HEART JOURNAL, 2005, 149 (03) :464-473
[4]   Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia [J].
Ballantyne, CM ;
Blazing, MA ;
King, TR ;
Brady, WE ;
Palmisano, J .
AMERICAN JOURNAL OF CARDIOLOGY, 2004, 93 (12) :1487-1494
[5]   A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia [J].
Bays, HE ;
Ose, L ;
Fraser, N ;
Tribble, DL ;
Quinto, K ;
Reyes, R ;
Johnson-Levonas, AO ;
Sapre, A ;
Donahue, SR .
CLINICAL THERAPEUTICS, 2004, 26 (11) :1758-1773
[6]   EFFECT OF PARTIAL ILEAL BYPASS-SURGERY ON MORTALITY AND MORBIDITY FROM CORONARY HEART-DISEASE IN PATIENTS WITH HYPERCHOLESTEROLEMIA - REPORT OF THE PROGRAM ON THE SURGICAL CONTROL OF THE HYPERLIPIDEMIAS (POSCH) [J].
BUCHWALD, H ;
VARCO, RL ;
MATTS, JP ;
LONG, JM ;
FITCH, LL ;
CAMPBELL, GS ;
PEARCE, MB ;
YELLIN, AE ;
EDMISTON, WA ;
SMINK, RD ;
SAWIN, HS ;
CAMPOS, CT ;
HANSEN, BJ ;
TUNA, N ;
KARNEGIS, JN ;
SANMARCO, ME ;
AMPLATZ, K ;
CASTANEDAZUNIGA, WR ;
HUNTER, DW ;
BISSETT, JK ;
WEBER, FJ ;
STEVENSON, JW ;
LEON, AS ;
CHALMERS, TC .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (14) :946-955
[7]   Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy [J].
Cannon, Christopher P. ;
Steinberg, Benjamin A. ;
Murphy, Sabina A. ;
Mega, Jessica L. ;
Braunwald, Eugene .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 48 (03) :438-445
[8]  
Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3
[9]   Clinical significance of statin pleiotropic effects - Hypotheses versus evidence [J].
Davidson, MH .
CIRCULATION, 2005, 111 (18) :2280-2281
[10]   Niemann-Pick C1 like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis [J].
Davis, HR ;
Zhu, LJ ;
Hoos, LM ;
Tetzloff, G ;
Maguire, M ;
Liu, JJ ;
Yao, XR ;
Iyer, SPN ;
Lam, MH ;
Lund, EG ;
Detmers, PA ;
Graziano, MP ;
Altmann, SW .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (32) :33586-33592